Intuniv (Guanfacine)

Guanfacine selectively activates alpha‑2A adrenergic receptors in the brainstem, which decreases the release of norepinephrine. This reduces sympathetic outflow, leading to lower blood pressure and improved attention and behavioral control in ADHD.

The appropriate dose of Intuniv is determined individually by a qualified prescriber based on the patient’s age, weight, clinical response, and tolerability. Dosage adjustments are made gradually to achieve the desired therapeutic effect.

Intuniv is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no well‑controlled studies in pregnant women. It should be used during pregnancy only if clearly needed, and breastfeeding mothers should consult their physician.

To place an order, submit an enquiry on the Intuniv product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Intuniv belongs to the alpha‑2 adrenergic agonist class, whereas many other ADHD drugs are stimulants such as methylphenidate. Intuniv is non‑stimulant, which may be preferred for patients who cannot tolerate stimulants or have comorbid conditions like anxiety.

Intuniv tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiration date.

Intuniv is taken orally as an extended‑release tablet, usually once daily in the morning or evening as directed by the prescriber. The tablet should be swallowed whole with water and not crushed or chewed.

Serious risks include significant bradycardia, severe hypotension, and syncope. Patients should be monitored for these events, especially during dose titration or if they have underlying cardiac conditions.

Intuniv is contraindicated in patients with known hypersensitivity to guanfacine or any tablet components. Caution is advised for individuals with severe cardiac conduction disorders, uncontrolled hypertension, or those taking interacting medications without medical supervision.